產(chǎn)品說明
拉坦前列素（游離酸）的類似物，前列腺素（PG）類似物
該產(chǎn)品包含在以下化合物庫中:
質(zhì)量控制
化學性質(zhì)
| CAS號 | 1088434-86-9 | ? | ? |
| 別名 |
| 分子式 | C32H38O5S3 | 分子量 | 598.8 |
| 溶解性 | Soluble in DMSO | 儲存條件 | Store at -20° |
?
實驗操作
| 細胞實驗[2]： |
| 細胞系 | |
| 溶解方法 | |
| 反應時間 | |
| 應用 | |
| 動物實驗[3]： |
| 動物模型 | |
| 劑量 | |
| 注意事項 | |
| References: |
產(chǎn)品描述
ACS 67 is an analog of latanoprost acid.
Latanoprost, an F-series prostaglandin (PG) analog, has been approved for use as an ocular hypotensive drug for the treatment of glaucoma clinically. Latanoprost is an isopropyl ester, a prodrug form which is converted to free latanoprost acid by endogenous esterase enzymes.
In vitro: In previous study, ACS 67 was found to be able to increase the reduced glutathione levels in normotensive pigmented rabbits significantly after single administration in a dose-dependent manner. Furthermore, in glaucomatous pigmented rabbits after repeated 5-day administration, ACS 67 could also increase the GSH levels when compared with latanoprost. In addition, it was found that ACS 67 could significantly increase the cGMP levels in glaucomatous pigmented rabbits and these data with the combination supported that the increase of cGMP was due to the sulfurated moiety of ACS 67. Moreover, the tolerability was measured in New Zealand albino rabbits at three different concentrations of ACS 67, and results indicated that ACS 67 was very well tolerated in Draize test [1].
In vivo: So far, there in no animal in vivo data reported.
Clinical trial: Up to now, ACS 67 is still in the preclinical development stage.
Reference:
[1] E.? Perrino, C. Uliva, C. Lanzi, et al. New prostaglandin derivative for glaucoma treatment. Bioorganic & Medicinal Chemistry Letters 19, 1639-1642 (2009).
溫馨提示：不可用于臨床治療。